ALVAC2 Melanoma: Phase II started

sanofi's sanofi pasteur S.A. vaccines unit began the open-label, U.S. and Canadian Phase II MEL11 trial in 120 patients to compare ALVAC2 plus granulocyte macrophage colony-stimulating factor (GM-CSF...